# Internal Review - Round 1

**Reviewer:** Claude Code (Internal)
**Paper:** State Insulin Copay Cap Laws and Diabetes Mortality: A Difference-in-Differences Analysis
**Date:** 2026-02-03

---

## PART 1: CRITICAL REVIEW

### 1. FORMAT CHECK

- **Length:** ~42 pages total including appendix and references. Main text appears to be 25+ pages. PASS.
- **References:** Bibliography covers key DiD methodology papers (Callaway & Sant'Anna, Goodman-Bacon, Sun & Abraham, Roth et al., de Chaisemartin & D'Haultfoeuille), health economics literature (Chandra et al., Sommers et al., Miller et al., Baicker et al.), and insulin-specific references (Rajkumar, Cefalu, Herkert). Adequate coverage.
- **Prose:** All major sections are written in full paragraphs. No bullet-point sections in Introduction, Results, or Discussion. PASS.
- **Section depth:** Each major section has 3+ substantive paragraphs. PASS.
- **Figures:** 5 figures (treatment rollout, raw trends, event study, Bacon decomposition, HonestDiD). All show visible data with proper axes.
- **Tables:** 5 tables with real numbers. Table 3 (main results) and Table 5 (heterogeneity) use tabularray format from modelsummary. All have actual regression output.

### 2. STATISTICAL METHODOLOGY

a) **Standard Errors:** All TWFE specifications report clustered SEs at state level in parentheses. CS-DiD reports bootstrap SEs. PASS.
b) **Significance Testing:** Stars reported for significant coefficients (e.g., COVID death rate). Main treatment effects are insignificant and correctly reported as such. PASS.
c) **Confidence Intervals:** 95% CIs reported in Table 4 (robustness). Main results table reports SEs; CIs can be computed. Adequate.
d) **Sample Sizes:** N=1157 reported for all main specifications. Heterogeneity subsamples report N. PASS.
e) **DiD with Staggered Adoption:** Paper uses Callaway-Sant'Anna (2021) as preferred estimator with never-treated control group. Also reports TWFE, Sun-Abraham, and Bacon decomposition. This is methodologically sound. PASS.

### 3. IDENTIFICATION STRATEGY

- **Credibility:** The identification relies on staggered adoption of copay cap laws across states. The paper acknowledges this is a reasonable but not perfect source of exogenous variation.
- **Parallel trends:** Event study shows pre-treatment coefficients fluctuating around zero with no discernible trend. Formal Wald test discussed. PASS.
- **Placebo tests:** The paper discusses that placebo tests on cancer and heart disease mortality cannot include post-treatment observations (all treatment is 2020+, placebo data is 1999-2017), so the test reduces to pre-treatment balance. This is honest but somewhat weak—the placebo test has limited power.
- **Robustness:** COVID exclusion, log specification, state trends, wild bootstrap, HonestDiD sensitivity analysis. Comprehensive battery. PASS.
- **Limitations:** Thorough discussion of outcome dilution, short post-treatment horizon, COVID confounding, IRA contamination. Well done.

**Concern:** The paper has only 17 treated states and a maximum of 4 post-treatment years (most have 1-3). This is acknowledged but the power implications deserve more explicit discussion. What is the minimum detectable effect (MDE)?

### 4. LITERATURE

Literature review is solid. Key methodology and policy papers are cited. Could consider adding:
- Mulcahy et al. (2021) on insulin pricing trends
- Basu et al. (2019) on insulin rationing consequences

### 5. WRITING QUALITY

a) **Prose vs. Bullets:** Full paragraphs throughout. PASS.
b) **Narrative Flow:** The paper tells a clear story: motivation (insulin crisis) → policy response (copay caps) → research design (staggered DiD) → results (null) → interpretation (dilution + short horizon). Strong logical arc.
c) **Sentence Quality:** Generally well-written with varied sentence structure. Active voice predominant. Some passages in the methods section are somewhat mechanical, but this is typical for methodology exposition.
d) **Accessibility:** Technical terms are generally explained. The "outcome dilution" concept is well motivated.
e) **Figures/Tables:** Publication quality. Clear axes, appropriate formatting.

### 6. CONSTRUCTIVE SUGGESTIONS

1. **Power analysis:** Add an explicit MDE calculation. With 17 treated states and 34 controls, what size effect could you detect at 80% power? This would contextualize the null result.
2. **COVID Death Rate coefficient display:** Table 3 Column 2 shows 0.000** for the COVID death rate coefficient. This is a scaling issue—rescale to per 100,000 so the coefficient is readable.
3. **Table numbering:** Verify that table numbering is sequential and consistent between text references and displayed tables. The tabularray tables from modelsummary may not have consistent numbering with the manually-created tables.

### 7. OVERALL ASSESSMENT

**Strengths:**
- Well-motivated research question with clear policy relevance
- Rigorous methodology using state-of-the-art DiD estimators
- Honest treatment of null result with thoughtful discussion of mechanisms
- Comprehensive robustness checks including HonestDiD
- Clean prose with strong logical flow

**Weaknesses:**
- Short post-treatment horizon limits power
- COVID death rate coefficient display issue (0.000**)
- No explicit MDE calculation
- Table numbering could be verified for consistency

This is a solid paper with an important null result that is well-executed and honestly discussed.

DECISION: MINOR REVISION
